The effect of propranolol on thyroid status was investigated by administering the drug in 2 therapeutic doses (80 mg b.d. and 120 mg b.d.) to 8 healthy volunteers and serially measuring total and free thyroid hormones and their major binding protein. Mean free T3 fell by 1.2 pmol/l (P< 0.05) whilst mean free T4 and mean rT3 rose by 3.3pmol/I (P<0.01) and 0.16nmol/I (P<0.01) respectively. Mean thyroxine binding globulin (TBG) fell by 1.2 mg/l (P< 0.001). Despite the change in free hormone levels there was no significant change in TSH. For the first time the effect of propranolol on circulating thyroid hormones and binding proteins in healthy subjects is apparent within one study. The biological significance of the change in free hormone levels is discussed.
Introduction
Beta-adrenoceptor blocking drugs (beta-blockers) have established a place in the treatment of thyrotoxicosis and it has been argued that their therapeutic effect, at least in part, may be mediated by a direct effect on thyroid hormone concentrations (Saunders et al., 1978) . Changes in total thyroid hormone levels have been reported in patients receiving beta-blockers for hypertension and angina (Kristensen & Weeke, 1977; Cooper et al., 1982) . There is then the suggestion that these drugs may directly alter thyroid status. In view of the large number of euthyroid patients taking beta-blocking agents, we felt it was important to investigate this possibility in detail. The biologically active component of circulating thyroxine (T4) and triiodothyronine (T3) is thought to be the free (unbound) fraction. Free T4 and free T3 account for only 0.03% and 0.3%, respectively, of total levels (Ekins, 1979) . This study was designed to clarify the effects of propranolol on thyroid status by administering the drug in 2 therapeutic doses to healthy volunteers and monitoring not only total T4 and T3, reverse T3, (rT3), TSH and thyroxine binding globulin (TBG) but also free T4 and free T3.
Methods
Eight euthyroid male volunteers aged 20 to 23 y were studied. Each had a normal clinical examination, full blood count and biochemical profile. Baseline thyroid function was assessed on 2 venous samples taken a week apart. Propranolol, 80 mg twice daily, was started on day 0 and continued until day 14. On day 15, after the morning blood sample, the dose was increased to 120mg twice daily for a further week. Propranolol was stopped on day 21. Blood was sampled for thyroid function tests on days 1, 2, 3, 7, 14, 15, 21, 22, 23 and 28 and compliance was checked by measuring plasma levels of propranolol on days 3, 7 and 15.
Total T3, T4 and rT3 were measured by in-house radioimmunoassay (Black et al., 1975; Evans et al., 1977) . Free T4, free T3 and TSH were measured using Amerlex kit methods and TBG by immunoelectrophoresis (Laurell, 1966) . The possibility of an in vitro effect of propranolol on the free hormone assays was examined by assaying a sample of normal serum containing different concentrations of propranolol (range 0 to 1000 ng/ml) for free T4 and T3. 
Results
There was a non-significant rise in total T4 during the treatment period and a return to baseline on stopping the beta-blocker. Total T3 levels remained stable throughout the study (Figure 1 ). Despite changes in total and free thyroid hormone levels ( Figure 2 ) there was no significant change in basal TSH concentration during the study period. Mean free T4 rose during the first week from a basal level of 19.8 (± s.e.m. 0.9) to 22.7 (± 1.0) pmol/l on day 7 (P <0.02). With some fluctuation in absolute values, it remained elevated for the rest of the treatment period, returning to baseline on stopping the drug (Figure 2 ).
The mean basal free T3 was 6.4 (± 0.3) pmol/l. There was no significant change during the period of low dose propranolol but there was a signficant fall to 5.2 (± 0.2) pmol/l (P<0.05) on 120mg b.d. and a sharp rise towards the basal value on stopping the drug (Figure 2 ).
Reverse T3 rose during the first week from a baseline level of 0.44 (± 0.02) to 0.57 (± 0.03) nmol/I (P < 0.01). It remained elevated throughout the treatment period, falling to basal levels after day 21.
TBG fell gradually from 9.4 (± 0.3) to a nadir of 8.2 (± 0.4) mg/l (P < 0.001) on day 22 and then showed a trend of gradual recovery during the post-treatment week (Figure 3 ). The change in T4/TBG ratio showed a very close correlation with the response of measured free T4 (r = 0.9; P < 0.001) (Figure 4 ).
The addition of propranolol to serum in vitro in increasing concentrations produced a slight but nonsignificant rise in measured free T4 and had no effect on measured free T3.
Discussion
Previously reported changes in total thyroid hormone levels in euthyroid subjects receiving propranolol may be summarized thus: total T3 may fall whilst reverse T3, and on higher doses, total T4 may rise. These changes, however, have never previously been described in one study (Cavalieri & Rivers, 1981) . Lotti et al. (1977) and Faber et al. (1979) noted a fall in T3 with propranolol 40 to 120 mg/d and the latter group also recorded a rise in reverse T3, but neither group found a change in total T4 levels. Kristensen & Weeke (1977) and Cooper et al. (1982) reported raised total T4 levels in patients receiving propranolol for essential hypertension and angina pectoris respectively; five of the six described by Cooper et al. (1982) also had raised levels of rT3 but both groups of patients had normal total T3 levels. The changes in total hormone concentrations found in our study -the rise in rT3, the non-significant rise in T4 and the stable T3 levels -are compatible with the observations of others. Kristensen & Weeke (1977) Figure 1 Total T4 and T3 and TSH levels during treatment with propranolol (hatched area) and in the follow-up week. of free T4 and free T3 in their study of 15 patients starting propranolol for essential hypertension. Their results differ from ours in that they observed a rise in free T4 but no change in free T3. Their patients were taking other antihypertensive drugs and the authors base their report on 2 blood samples for each individual taken 30 days apart, two factors which may have reduced the sensitivity of their study.
In this report, changes in free thyroid hormones parallelled those described for total circulating hormones, and for the first time the effects of propranolol on thyroid hormones, total and free, and their major binding protein are apparent in one study. Most T3 and rT3 is produced by the monodeiodination of T4 in peripheral tissues -liver and kidney -rather than in the thyroid (Chopra et al., 1978) . The changes in free T4, free T3 and rT3 presented here provide strong supporting evidence for an inhibitory influence of 
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Free T4 (pmol/1) Figure 4 Correlation of estimated free T4 (T4/TBG ratio) and measured free T4 during the study period (on and off propranolol). r = 0.9; P < 0.001.
propranolol on 5' monodeiodinase. This enzyme is responsible for the monodeiodination of T4 to T3 (Chopra et al., 1978) and rT3 to T2, hence T3 production falls and rT3 clearance is reduced if its activity is inhibited. The mechanism by which propranolol exerts this inhibitory effect is unclear. The property is not confined to propranolol but is shared by some other beta-blockers. (Perrild et al., 1983) . DL-propranolol, which has no known beta-blocking activity, has also been reported to decrease T3 and increase rT3 levels (Heyma et al., 1980) . The fall in TBG that occurs during propranolol therapy was first noted by Wilkinson et al. (1983) . It occurs in euthyroid subjects and in thyrotoxic patients once rendered euthyroid. It cannot be attributed to changes in plasma volume as serum albumin levels remain unaffected. The very close correlation between the T4/TBG ratio (an estimate of free T4) and the measured free hormone (Figure 4) suggests that the fall in TBG does not invalidate the use of the T4/TBG ratio in patients taking propranolol. Furthermore, this close correlation affords independent evidence supporting the argument that the rise in free T4 is genuine and not explained by an effect of propranolol on the free T4 assay. In contrast, there was no correlation between the change in T3/TBG ratio and the response of free T3.
Interpretation of the biological significance of an 18% fall in free T3 and a concurrent 20% rise in free T4 is complicated by the lack of a definitive standard by which to assess thyroid status. In euthyroid subjects, serum levels of free T4 and free T3 remain remarkably constant with time (unpublished data). A fall of 1.2 pmol/l in free T3 and a rise of around 3.0 pmol/l in free T4 in absolute terms in healthy volunteers is unphysiological. The net effect of these divergent responses on metabolism depends upon the relative potencies of free T4 and free T3. It has been estimated that T4 is 2 to 4 times less potent in stimulating calorigenesis than T3, and that T4 has no catabolic activity (Perrild et al., 1983) . Therefore the overall effect may be that there is a net fall in catabolic activity.
At present the two most sensitive indicators of 'adequacy' of circulating thyroid hormone levels are the serum TSH level and its response to thyrotrophin releasing hormone (TRH). In this study, there was no significant change in TSH levels. Cooper et al. (1982) included TRH stimulation in their series ofpatients on high-dose propranolol; they obtained normal or blunted, rather than exaggerated, TSH responses to TRH stimulation. Thus there is no evidence as yet to suggest that the pituitary appreciates treatment with propranolol as drug-induced hypothyroidism but the definitive test awaits the discovery of a sensitive assay of biological activity of thyroid hormones at the tissue level.
